These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24252545)

  • 21. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
    Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
    Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
    Ellis DA; Blazel JK; Tran CV; Ruebsam F; Murphy DE; Li LS; Zhao J; Zhou Y; McGuire HM; Xiang AX; Webber SE; Zhao Q; Han Q; Kissinger CR; Lardy M; Gobbi A; Showalter RE; Shah AM; Tsan M; Patel RA; LeBrun LA; Kamran R; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6047-52. PubMed ID: 19796938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
    Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
    J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of potency and pharmacokinetics of tricyclic indole derived inhibitors of HCV NS5B polymerase. Identification of ester prodrugs with improved oral pharmacokinetics.
    Venkatraman S; Velazquez F; Gavalas S; Wu W; Chen KX; Nair AG; Bennett F; Huang Y; Pinto P; Jiang Y; Selyutin O; Vibulbhan B; Zeng Q; Lesburg C; Duca J; Heimark L; Huang HC; Agrawal S; Jiang CK; Ferrari E; Li C; Kozlowski J; Rosenblum S; Shih NY; Njoroge FG
    Bioorg Med Chem; 2014 Jan; 22(1):447-58. PubMed ID: 24275348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
    Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
    J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
    Gentles RG; Ding M; Bender JA; Bergstrom CP; Grant-Young K; Hewawasam P; Hudyma T; Martin S; Nickel A; Regueiro-Ren A; Tu Y; Yang Z; Yeung KS; Zheng X; Chao S; Sun JH; Beno BR; Camac DM; Chang CH; Gao M; Morin PE; Sheriff S; Tredup J; Wan J; Witmer MR; Xie D; Hanumegowda U; Knipe J; Mosure K; Santone KS; Parker DD; Zhuo X; Lemm J; Liu M; Pelosi L; Rigat K; Voss S; Wang Y; Wang YK; Colonno RJ; Gao M; Roberts SB; Gao Q; Ng A; Meanwell NA; Kadow JF
    J Med Chem; 2014 Mar; 57(5):1855-79. PubMed ID: 24397558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening.
    Kim ND; Chun H; Park SJ; Yang JW; Kim JW; Ahn SK
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3329-34. PubMed ID: 21531135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.
    Harper S; Avolio S; Pacini B; Di Filippo M; Altamura S; Tomei L; Paonessa G; Di Marco S; Carfi A; Giuliano C; Padron J; Bonelli F; Migliaccio G; De Francesco R; Laufer R; Rowley M; Narjes F
    J Med Chem; 2005 Jul; 48(14):4547-57. PubMed ID: 15999993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
    Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
    ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.
    Vandyck K; Cummings MD; Nyanguile O; Boutton CW; Vendeville S; McGowan D; Devogelaere B; Amssoms K; Last S; Rombauts K; Tahri A; Lory P; Hu L; Beauchamp DA; Simmen K; Raboisson P
    J Med Chem; 2009 Jul; 52(14):4099-102. PubMed ID: 19507864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.
    Narjes F; Crescenzi B; Ferrara M; Habermann J; Colarusso S; Ferreira Mdel R; Stansfield I; Mackay AC; Conte I; Ercolani C; Zaramella S; Palumbi MC; Meuleman P; Leroux-Roels G; Giuliano C; Fiore F; Di Marco S; Baiocco P; Koch U; Migliaccio G; Altamura S; Laufer R; De Francesco R; Rowley M
    J Med Chem; 2011 Jan; 54(1):289-301. PubMed ID: 21141896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.
    Paparin JL; Amador A; Badaroux E; Bot S; Caillet C; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Giulia Loi A; McCarville J; Mascia V; Milhau J; Onidi L; Pierra C; Rahali R; Rosinosky E; Sais E; Seifer M; Surleraux D; Standring D; Dousson CB
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2634-2640. PubMed ID: 28416131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
    Yu H; Fang Y; Lu X; Liu Y; Zhang H
    Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors.
    Canales E; Carlson JS; Appleby T; Fenaux M; Lee J; Tian Y; Tirunagari N; Wong M; Watkins WJ
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4288-92. PubMed ID: 22664130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Giuliano C; Fiore F; Di Marco A; Padron Velazquez J; Bishop A; Bonelli F; Gonzalez-Paz O; Marcucci I; Harper S; Narjes F; Pacini B; Monteagudo E; Migliaccio G; Rowley M; Laufer R
    Xenobiotica; 2005; 35(10-11):1035-54. PubMed ID: 16393860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
    Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors.
    Barnes-Seeman D; Boiselle C; Capacci-Daniel C; Chopra R; Hoffmaster K; Jones CT; Kato M; Lin K; Ma S; Pan G; Shu L; Wang J; Whiteman L; Xu M; Zheng R; Fu J
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3979-85. PubMed ID: 24986660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).
    LaPlante SR; Bös M; Brochu C; Chabot C; Coulombe R; Gillard JR; Jakalian A; Poirier M; Rancourt J; Stammers T; Thavonekham B; Beaulieu PL; Kukolj G; Tsantrizos YS
    J Med Chem; 2014 Mar; 57(5):1845-54. PubMed ID: 24159919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.
    Krueger AC; Randolph JT; DeGoey DA; Donner PL; Flentge CA; Hutchinson DK; Liu D; Motter CE; Rockway TW; Wagner R; Beno DW; Koev G; Lim HB; Beyer JM; Mondal R; Liu Y; Kati WM; Longenecker KL; Molla A; Stewart KD; Maring CJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3487-90. PubMed ID: 23664214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.